Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo

NCT04818346 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04818346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04818346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2021
Completion date
May 24, 2023
Enrollment
171 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

nonsegmental vitiligo